Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.48 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.47 |
| ▸ | ITGAL | P20701 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 4/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308989 | 0.87 | ITGB2 (0.59) | SLC15A2ITGB2ICAM1ITGALCA1 | |
| SCHEMBL1229751 | 0.87 | ITGB2 (0.59) | SLC15A2ITGB2ICAM1ITGALCA1 | |
| SCHEMBL1161012 | 0.87 | ITGB2 (0.59) | SLC15A2ITGB2ICAM1ITGALCA1 | |
| SCHEMBL23380979 | 0.86 | LNPEP (0.43) | SLC15A2ITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL21955470 | 0.86 | REN (0.44) | SLC15A2ITGB2ICAM1ITGALCA1 | |
| SCHEMBL21955489 | 0.86 | LNPEP (0.43) | SLC15A2ITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL27469252 | 0.86 | ITGB2 (0.58) | SLC15A2ITGB2ICAM1ITGALCA1 | |
| SCHEMBL23380976 | 0.85 | LNPEP (0.42) | SLC15A2ITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL21529460 | 0.85 | REN (0.46) | SLC15A2ITGB2ICAM1ITGALREN | |
| SCHEMBL28354383 | 0.85 | REN (0.46) | SLC15A2ITGB2ICAM1ITGALREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | MARENGO THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12630845-B2 | AAV capsid variants for targeting human glioblastoma cells | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4683651-A2 | TCR TARGETING MOLECULES AND USES THEREOF | Marengo Therapeutics, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| CN-119740304-A | Aircraft operation simulation method, system and equipment based on cellular automaton | 深圳市城市交通规划设计研究中心股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250099579-A1 | MULTISPECIFIC MOLECULES BINDING TO TCR AND USES THEREOF | MARENGO THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2025022361-A1 | MATERIALS AND METHODS FOR CELL GROWTH | JANSSEN BIOTECH, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024197082-A2 | TCR TARGETING MOLECULES AND USES THEREOF | MARENGO THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| EP-4320147-A2 | MULTIFUNCTIONAL MOLECULES BINDING TO TCR AND USES THEREOF | Marengo Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117200783-A | High-speed driving circuit supporting mutual switching of LVDS transmission protocol and CML transmission protocol | 成都纳能微电子有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4187424-A1 | DOCUMENT AUTHENTICATION SYSTEM AND METHOD | OTP Bank Nyrt. (HU) | 2023-05-31 | — | — | EP | disclosed |
| US-20220333136-A1 | AAV CAPSID VARIANTS TARGETING HUMAN GLIOBLASTOMA CELLS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED. (US) | 2022-10-20 | — | — | US | disclosed |
| WO-2022216993-A2 | MULTIFUNTIONAL MOLECULES BINDING TO TCR AND USES THEREOF | MARENGO THERAPEUTICS, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | SLC15A2 3554/4885ITGB2 4171/4885ICAM1 4379/4885 |
| US-12630845-B2 | AAV capsid variants for targeting human glioblastoma cells | ATP6V1B2, CBFB, ETV1 | SLC15A2 800/4885ITGB2 600/4885ICAM1 3522/4885 |
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | CD2, CD4, CD47 | SLC15A2 3769/4885ITGB2 276/4885ICAM1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.